BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Nektar Cuts 70% of Workforce on Heels of BMS-Partnered Collapse

  Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after BMS abandoned its clinical collaboration program with Nektar.

  April 26, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Protagonist Forges Ahead with UC Drug On Strength of Low Dose Data

  Protagonist Therapeutics’ Phase II study of an ulcerative colitis treatment failed to meet its primary endpoint at a higher dosage amount. Even so, the company remains optimistic about the drug’s future.

  April 26, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Concerns Resolved, FDA Clears Way for Gamida Cell’s Lymphoma Trial

  Gamida Cell reported that the FDA had lifted its clinical hold on its cryopreserved formulation of GDA-201. It expects to launch a Phase I/II drug trial for those indications this year.

  April 26, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Pfizer, Valneva Lyme Vaccine Shows Promise in Pediatric Patients

  Pfizer and its partner, Valneva, have announced positive Phase II data from its trial of vaccine candidate VLA15 in a pediatric population. VLA15 is intended to prevent Lyme Disease (LD).

  April 26, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Sanonia, Black Diamond Fall Victim To Rough Biotech Market

  The first quarter hasn’t been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.

  April 26, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Apertura Launches Leveraging Harvard, MIT Gene Therapy Platforms: Updated

  With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.

  April 26, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Editas, VBL and Pharming Score Regulatory Wins On Development Journey

  Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.

  April 26, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  The 9 Things Wildly Successful Biotechs Have in Common

  Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.

  April 26, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Sandoz, Zolgensma, Drive Strong Q1 for Novartis

  Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8%, mostly outside of the United States.

  April 26, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Study: Inhibiting ATX Improves Ability to Recover from Stroke

  A new approach to improving a patient’s ability to recover from a stroke is discussed in an article published this month in Science Translational Medicine.

  April 26, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano